Introduction
Despite the reduced incidence, gastric cancer is the second most common among cancer-related deaths in the word. In two-third of patients with gastric cancer are diagnosed with metastatic disease (Kamangar et al., 2006; Jemal et al., 2011) . Without effective treatment, the median survival for metastatic disease is 3 to 5, however it may be extended 8-12 months with the platinum and taxane-containing regimens (Van Cutsem et al., 2006; Roth et al., 2007) . Randomized trials have shown that systemic chemotherapy resulted in a significant survival benefits when compared with best supportive care (Murad et al., 1993; Pyrhonen et al., 1995; Glimelius et al., 1997) . The meta-analysis by Wagner et al. suggests that the combination chemotherapy response rates over monotherapy alone in patients with advanced gastric cancer (Wagner et al., 2006) . In the Tax 325 study, two regimens were compared; 75 mg/m² docetaxel and cisplatin on day 1 and 750 mg/m² 5-Fluorouracil continuous infusion per day on days 1-5, every 3 weeks (DCF) versus cisplatin 100 mg/m² on day 1 and 1000 mg/ 1-5, every 4 weeks (CF). The DCF arm response rates (37 vs 25%) and overall survival (OS) higher than CF arm, while the toxicities of grade 3 to 4 was higher in the DCF arm (Van Cutsem et al., 2006) . Very different prognostic factors in several studies have been identified for survival in patients with advanced gastric cancer (Tsujitani et al., 2001; Chau et al., 2004; Yoshida et al., 2004; Kim et al., 2008; Maroufizadeh., 2012) . Systemic chemotherapy for patients with gastric cancer has limited impact on OS due to not only a low response rates, but also severe side effects. Determining the prognostic factors of survival for metastatic gastric cancer patients with first-line chemotherapy treated patients can help physicians in the decision-making process for individual patients.
We performed a retrospective analysis of prognostic factors in the metastatic gastric cancer patients treated with first-line DCF chemotherapy.
Materials and Methods

Patient Population
We retrospectively reviewed 107 locally advanced or metastatic gastric cancer patients who were treated DCF as first-line treatment between June 2007 and August 2011. All had advanced gastric cancer. Patients who had received prior treatment were excluded.
Treatment and Assessment
The DCF protocol included 50-75 mg/m 2 docetaxel and cisplatin on day 1 and 500-750 mg/m 2 /day 5-FU infusion for 5 days, repeated every 3 weeks. Imaging studies were documented by computed tomography at baseline and every three cycles for patients.
The responses to chemotherapy were measured according to Response Evaluation Criteria in Solid Tumors (RECIST).
Factors Analyzed
Twenty-eight clinical variables [age, gender, prior gastrectomy, performance status, location of primary tumor, stage, grade, histology, diabetes mellitus, hypertension, weight loss, dose reduction, second-line chemotherapy, liver metastasis, lung metastasis, bone metastasis, peritoneum metastasis, ascites, hemoglobin (Hb), WBC count, platelet (PLT) count, serum albumin (alb), serum calcium, serum alkaline phosphatase (ALP), serum lactic dehydrogenase (LDH), serum total bilirubin, serum carcinoembryonic antigen (CEA) level and serum carbohydrate antigen 19-9 (CA19-9) level] were chosen on the basis of previously published clinical trials.
Statistical Analysis
All of the analyses were performed using the SPSS statistical software program package (SPSS version 11.0 for windows). The differences of the clinical characteristics between the two groups were analyzed by chi-square test and student t test. Overall survival (OS) was calculated with the log-rank test. The Kaplan-Meier method was used survival curves. The Cox proportional hazards regression model was used to determine statistical significant variables related to survival. Differences were assumed to be significant when the P value was less than 0.05.
Results
Patient Characteristics
Between June 2007 to August 2011, 107 untreated patients with locally advanced and metastatic gastric cancer were enrolled in this study. The median age of patients was 52 years (range 23-76) with 69 males and 38 females. Ninety-two patients (86%) were diagnosed as having metastatic gastric cancer and 15 patients (14%) had locally advanced gastric cancer. 28 patients (26.2%) received second-line chemotherapy. The median OS was 9.0 months. The patient's baseline characteristics are listed in Table 1 .
Prognostic Factor Analysis
The results of univariate analysis are summarized in Table 2 . Among the twenty-eight variables of univariate analysis, eight variables were identified to have prognostic patients (Yoshida et al., 2004; Lee et al., 2007; Kim et al., 2008) . Similarly performance status found that the prognostic importance for survival in our study.
The weight loss is usually associated with gastroesophageal malignancy. Increased weight loss may represent a more aggressive tumour biological behaviour and increased tumour burden. Weight loss was found to be an independent prognostic factor of survival (Andreyev et al., 1998; Sougioultzis et al., 2010) , while Kanagavel et al. (2010) no observed significant effect for overall survival. In our study, weight loss is found to be independent risk factor for survival.
The prognostic significance of peritoneal metastases and ascites with advanced gastric cancer was investigated in few clinical studies. It has been shown significantly associated with in some clinical studies (Kim et al., 2008; Chau et al., 2004; Sadeghi et al., 200) , whereas Kanagavel et al.(2010) had no significant effect for overall survival. In our retrospective study, peritoneum metastasis and ascites were found to be an independent prognostic factor for survival.
Anemia is common among advanced gastric cancer patients. Anemia may be caused by many factors. These include a result of bleeding, chemotherapy-induced myelosuppression, marrow infiltration by tumor, hemolysis, nutritional deficiency or cytokine-mediated anemia of chronic disease. The previously by many authors (Chau et al., 2004; Park et al., 2006; Kim et al., 2008; Kanagavel et al., 2010) had showed that the low hemoglobin level in patients with advanced gastric cancer is correlated independently with poor prognosis, while in some studies (Lee et al., 2007; Kim et al., 2008) , the low hemoglobin level had no significant effect for overall survival. In our analysis, anemia was found to be an independent prognostic factor on survival in patients receiving first-line therapy.
The histological patterns of gastric cancer also vary from country to country. These may depend on the prevalent socioeconomic conditions, genetic and environmental factors. The prognostic significance of histological subtype with advanced gastric cancer patients was investigated in few clinical trials (Kanagavel et al., 2010) . Kanagavel et al. had no prognostic importance for survival. Unlike earlier studies, our study found that histological subtype is an independent risk factor for survival.
The present study has some limitations which need to be taken into account. Firstly, its retrospective study. Secondly, we did not evaluate molecular characteristics of the tumor. Thirdly, there was the small number of patients.
In conclusion, age, weight loss, liver metastasis, serum CEA level and serum CA19-9 level were identified as important prognostic factors in advanced gastric cancer patients who were undergoing first-line palliative gemcitabine alone or gemcitabine plus cisplatin. These findings may also facilitate pretreatment prediction of survival and can be used for selecting patients for treatment. However, before final conculsion can be drawn, larger prospective and clinical trials need to be conducted for confirmation. 
Discussion
Systemic chemotherapy for patients with gastric cancer has limited impact on OS due to not only a low response rates, but also severe side effects. Patients eligible for chemotherapy should be selected carefully. This retrospective study analyzed prognostic factors for survival in advanced gastric cancer patients who were undergoing first-line palliative DCF chemotherapy.
On univariate analysis, nine of twenty-eight potential factors were identified as significant prognostic factors for survival. However, only six independent significant prognostic factors were found on multivariate analysis: performance status, weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level.
A poor performance status is usually accepted a negative prognostic factor for all cancer patients (Chau et al., 2004; Mitry et al., 2004; Hoang et al., 2005; Krishnan et al., 2006; Lee et al., 2007) . The importance of this marker was also confirmed in advanced gastric cancer
